| Literature DB >> 31138472 |
Fengbin Song1, Guozhang Xu2, Michael D Gaul3, Baoping Zhao3, Tianbao Lu3, Rui Zhang3, Renee L DesJarlais3, Karen DiLoreto3, Norman Huebert3, Brian Shook3, Dennis Rentzeperis4, Rosie Santulli4, Annette Eckardt4, Keith Demarest4.
Abstract
A novel series of indazole/indole derivatives were discovered as glucagon receptor (GCGR) antagonists through scaffold hopping based on two literature leads: MK-0893 and LY-2409021. Further structure-activity relationship (SAR) exploration and optimization led to the discovery of multiple potent GCGR antagonists with excellent pharmacokinetic properties in mice and rats, including low systemic clearance, long elimination half-life, and good oral bioavailability. These potent GCGR antagonists could be used for potential treatment of type II diabetes.Entities:
Keywords: Diabetes mellitus; Glucagon; Glucagon receptor antagonist; Indazole; Indole
Year: 2019 PMID: 31138472 DOI: 10.1016/j.bmcl.2019.05.036
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823